A vaccine against respiratory syncytial virus (RSV) could reduce hospitalizations in children by more than 80%. This was reported by daily mail.
Scientists tested the RSV vaccine Nirsevimab in a clinical study involving more than eight thousand children under the age of one in the UK, France and Germany. Patients received the vaccine before the RSV season, which usually begins in October.
Hospitalizations for lower respiratory tract infections caused by RSV were 83% lower among those who received the vaccine. Serious infection occurred in 5 (0.1%) patients in the vaccinated group and in 19 (0.5%) patients in the unvaccinated group. Side effects of the drug were mostly mild.
RSV is a seasonal virus that usually causes mild cold-like symptoms. However, the disease often leads to more serious problems such as pneumonia and death.
Nirsevimab is a single-dose vaccine created by Sanofi and AstraZeneca. It has already received approval from Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) and could be part of the campaign against RSV next autumn.
previous doctors in the name The most effective drugs for hand arthritis.